{"nctId":"NCT02475629","briefTitle":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","startDateStruct":{"date":"2015-08"},"conditions":["HIV"],"count":40,"armGroups":[{"label":"Open-Label Ibalizumab plus OBR","type":"EXPERIMENTAL","interventionNames":["Biological: ibalizumab","Drug: Optimized Background Regimen (OBR)"]}],"interventions":[{"name":"ibalizumab","otherNames":["TNX-355","Hu1A8"]},{"name":"Optimized Background Regimen (OBR)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are capable of understanding and have voluntarily signed the informed consent document\n* Have documented HIV-1 infection by official, signed, written history (e.g., laboratory report), otherwise an HIV-antibody test will be performed\n* Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before Screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV\n* Are able and willing to comply with all protocol requirements and procedures\n* Have a life expectancy that is \\>6 months.\n* Have a viral load \\>1,000 copies/mL and documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications as measured by resistance testing\n* Have a history of at least 6 months on antiretroviral treatment\n* Are receiving a stable highly active antiretroviral regimen for at least 8 weeks before Screening and are willing to continue that regimen until Day 14, OR (in the past 8 weeks) have failed and are off therapy and are willing to stay off therapy until Day 14\n* Have full viral sensitivity/susceptibility to at least one antiretroviral agent, other than ibalizumab, as determined by the screening resistance tests and be willing and able to be treated with at least one agent to which the patient's viral isolate is fully sensitive/susceptible according to the screening resistance tests as a component of OBR\n* If sexually active, are willing to use an effective method of contraception during the study and for 30 days after the last administration of the study drug\n\nExclusion Criteria:\n\n* Any active AIDS-defining illness per Category C conditions according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection, with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to HIV\n* Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study\n* Any significant acute illness within 1 week before the initial administration of study drug\n* Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.\n* Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 12 weeks before Enrollment\n* Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)\n* Any vaccination within 7 days before Enrollment\n* Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding\n* Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations\n* Any previous clinically significant allergy or hypersensitivity to any excipient in the ibalizumab formulation\n* Any radiation therapy during the 28 days before first administration of investigational medication\n* Any Grade 3 or 4 laboratory abnormality according to the Division of AIDS grading scale, except for the following asymptomatic Grade 3 events triglyceride elevation total cholesterol elevation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF","description":"Proportion of participants (%) achieving a viral load reduction of at least 0.5 log from baseline (Day 7)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.825","spread":null}]}]}]},{"type":"PRIMARY","title":"Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol Correct","description":"Proportion of patients (%) with a viral load decrease of at least 0.5 log 10 from baseline (day 7)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.846","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy: Proportion of Patients With Undetectable Viral Load: ITT-MEF","description":"Proportion of patients with undetectable Viral Load (\\<50 copies/mL, and \\<400 copies/mL)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".425","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".525","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy: Proportion of Patients With Undetectable HIV-RNA Levels: Protocol Correct","description":"Proportion of patients (%) with HIV-RNA levels \\< 50 copies/mL and \\< 400 copies/mL at Week 25/End of Study","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".654","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".808","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Viral Load as a Measure of Efficacy - ITT-MEF","description":"Mean change from Day 7/Baseline in log 10 vial load measured at Day 14","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.07","spread":"0.618"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Viral Load as a Measure of Efficacy - Protocol Correct","description":"Mean change from Day 7/Baseline in Log 10 viral load measured at Day 14","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"0.641"}]}]}]},{"type":"SECONDARY","title":"End of Study Viral Load Reductions as a Measure of Efficacy - Intent to Treat Analysis","description":"Proportion of patients achieving a \\>/= 0.5 log10 and \\>/= 1.0 log10 decrease from Day 7/Baseline in viral load at Week 25/End of Study","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".625","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".550","spread":null}]}]}]},{"type":"SECONDARY","title":"End of Study Viral Load Reductions as a Measure of Efficacy - Protocol Correct Analysis","description":"Proportion of patients achieving a \\>/= 0.5 log10 and \\>/= 1.0 log10 decrease from Day 7/Baseline in viral load at Week 25/End of Study","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".962","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".846","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in CD4+ Cell Count as a Measure of Efficacy and Safety - ITT","description":"Mean change from Day 7/Baseline in CD4+ cell count at Week 25/End of Study","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":"105.75"}]}]}]},{"type":"SECONDARY","title":"Mean Change in CD4+ Cell Count as a Measure of Efficacy and Safety - Protocol Correct","description":"Mean change from Day 7/Baseline in CD4+ cell count at Week 25/End of Study","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":"114.35"}]}]}]},{"type":"SECONDARY","title":"Safety: Proportion of Participants Experiencing Adverse Events","description":"Proportion of participants experiencing at least one treatment emergent adverse event to week 25/End of Study","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Experiencing Adverse Event Related to Study Drug as a Measure of Safety and Tolerability","description":"Proportion of participants experiencing a treatment emergent adverse event determined by the investigator to be related to study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Experiencing Serious Adverse Event as a Measure of Safety and Tolerability","description":"Proportion of participants experiencing at least one serious treatment emergent adverse event, excluding death","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Discontinuing Study Drug Due to Adverse Event","description":"Proportion of participants discontinuing study drug due to occurrence of treatment emergent adverse event","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Experiencing Adverse Event Grade 3 and Higher as a Measure of Safety and Tolerability","description":"Proportion of participants experiencing treatment emergent adverse event Grade 3 and higher","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Experiencing Adverse Event With Death as Outcome as a Measure of Safety and Tolerability","description":"Proportion of participants experiencing treatment emergent adverse event with death as the outcome, regardless of relationship to study drug","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Experiencing New AIDS-defining Adverse Event According to CDC Criteria as a Measure of Safety and Tolerability","description":"Proportion of participants experiencing treatment emergent adverse event that is AIDS-defining by the CDC adverse event classification criteria for HIV infection","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pharmacodynamics: CD4 Receptor Occupancy","description":"% of CD receptors occupied by ibalizumab on CD4+ T-cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.40","spread":"32.909"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":40},"commonTop":["Diarrhoea","Nausea","Fatigue","Rash","Dizziness"]}}}